Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 44
Filter
2.
Platelets ; 6(6): 408-11, 1995.
Article in English | MEDLINE | ID: mdl-21043773

ABSTRACT

In insulin-dependent diabetics (IDDM) and peripheral occlusive arterial disease (POAD), inhibition of platelet aggregation (PA) by PGI(2) and PGE(1) was reduced (p <0.02) compared with non-diabetics and POAD as well as with healthy subjects at a similar extent of PA (in the 3 groups). c-AMP content in resting platelets of IDDM and chronic renal failure was decreased (mean ± SD in pmo1/2.5 × 10(8) platelets): 5.3 ± 1.1 compared with the content in healthy subjects: 8.0 ± 1.12 and P< 0.012. Moreover, c-AMP content in PGE(1)-stimulated platelets was also reduced in these patients. Our results indicate that diabetic patients are characteristically less sensitive to inhibition by the 2 prostanoids, presumably through attenuated activity of the c-AMP generating system.

6.
Platelets ; 4(1): 45-8, 1993.
Article in English | MEDLINE | ID: mdl-21043853

ABSTRACT

Compared to normal controls, platelets from myotonic dystrophy (MyD) patients, released significantly more ß-thromboglobulin (ßTG) and generated more thromboxane B(2) (TXB(2)) when platelet aggregation was induced by ADP (1.5 µM) or epinephrine 1 µM. TXB(2) generation in MyD platelets at 1 and 3 min was positively correlated (p < 0.05) to platelet aggregation (PA). This suggests that, 1 min after the addition of the PA inducers, the platelets of MyD patients are already at the second (irreversible) phase of PA. Together with our previous data, these results may indicate hyperactivity of platelets caused by a membrane abnormality in MyD.

7.
Eur J Haematol ; 47(5): 326-32, 1991 Nov.
Article in English | MEDLINE | ID: mdl-1836999

ABSTRACT

Platelet aggregation (PA) induced by ADP, collagen and epinephrine, plasma levels of beta-thromboglobulin (beta TG) and thromboxane B2 (TXB2) and serum TXB2 generation were studied in 11 patients with primary thrombocytosis (7 with essential thrombocythaemia and 4 with polycythaemia vera) and compared with 16 healthy subjects. 5 patients suffered from peripheral vascular ischaemia and another 3 had venous thrombosis, but none had bleeding complications. The patients showed an abnormal pattern of platelet function and of thromboxane generation distinct from the healthy subjects in three aspects. a) Shape change was 5-26 times greater, the lag-time of collagen PA was 2.3-2.9 times longer and the extent of epinephrine PA was nil or very low. ADP- or collagen-induced PA was also reduced (p less than 0.02). b) Plasma TXB2 generation (corrected to a normal platelet concentration) stimulated by the three PA inducers was within the range of the healthy subjects in spite of the reduced extent of PA. c) Plasma beta TG level and serum TXB2 generation (both corrected to a normal platelet concentration) were 2.9-7.1 times higher (p less than 0.001) indicating enhanced in vivo platelet activation and possibly increased thrombin generation. These abnormalities were not detected in another 4 patients with secondary thrombocytosis. The abnormal pattern of platelet function and thromboxane generation can be a useful laboratory method in the evaluation of patients with primary thrombocytosis. It might also explain the thrombotic complications which occurred in 8 of the patients in a manner such that increased or normal TXB2 generation overcomes the reduced extent of PA. In this respect, the pronounced serum TXB2 synthesis might be a marker of intravascular thrombosis.


Subject(s)
Platelet Aggregation/physiology , Thrombocytosis/blood , Thrombosis/etiology , Thromboxane B2/blood , beta-Thromboglobulin/metabolism , Female , Humans , Ischemia/etiology , Male , Middle Aged , Thrombocytosis/complications
10.
Thromb Haemost ; 62(3): 840-5, 1989 Nov 24.
Article in English | MEDLINE | ID: mdl-2531938

ABSTRACT

Platelet aggregation (PA), platelet thromboxane B2 (TXB2) generation and 14C 5-hydroxytryptamine (5HT) release were studied in 13 patients with unstable angina, and compared to 14 patients with stable angina and 16 healthy controls. A typical pattern, distinct in 4 aspects from stable angina patients or controls, was observed in the unstable angina patients. ADP or collagen induced shape change was 3-4 times greater, the extent of epinephrine induced PA was nil or very low, the extent of collagen induced 14C 5HT release was also reduced while collagen induced platelet TXB2 generation was increased in spite of a reduced extent of PA. The extent of ADP or collagen induced PA was also significantly reduced. These results indicate a platelet membrane abnormality occurring presumably during contact of the circulating platelets with a non-occlusive thrombus observed at sites of ruptured plaques in unstable angina patients. Since also the pattern (20-30% overlap with control values) was distinct from that of stable angina patients, it might indicate an active thrombotic process. Plasma beta-thromboglobulin (beta TG) and TXB2 levels and serum TXB2 generation were also studied in the cardiac patients and controls and in another 10 patients with advanced peripheral occlusive arterial disease (POAD). Plasma beta TG and TXB2 levels were slightly elevated in the unstable angina patients and markedly elevated in the POAD patients. Serum TXB2 generation was, however, elevated in the stable angina patients (p less than 0.002) and more so in the unstable angina patients (p less than 0.001) compared to controls or to POAD patients. This was presumably mediated through enhanced thrombin generation. These results suggest that the measured plasma beta TG variable in the unstable angina patients is not useful in the assessment of in vivo platelet activation. It is presumably reflecting the sum of local enhanced platelet activation (at sites of ruptured plaques) and of reduced function of the "defective" circulating platelets. The ability of the platelets of unstable angina patients to generate large amounts of TXB2 if occurring in vivo might induce an intense coronary vasospasm.


Subject(s)
Angina Pectoris/blood , Angina, Unstable/blood , Blood Platelets/physiology , Thromboxane B2/biosynthesis , Adult , Aged , Arterial Occlusive Diseases/blood , Humans , Middle Aged , Platelet Aggregation , Serotonin/metabolism , beta-Thromboglobulin/analysis
11.
J Neurol Sci ; 84(2-3): 239-46, 1988 Apr.
Article in English | MEDLINE | ID: mdl-2967890

ABSTRACT

Platelet aggregation (PA) induced by (-)-epinephrine and adenosine diphosphate (ADP) was studied in 16 patients with myotonic dystrophy (MyD) and 14 healthy subjects. Plasma beta-thromboglobulin level (beta-TG), a useful marker of in vivo platelet release reaction, as well as in vitro 5-[14C]hydroxytryptamine (5-HT) release, were also studied. The extent of PA induced by (-)-epinephrine at 1 and 3 min and by ADP at 3 min was significantly higher in the patients than in controls. Plasma beta-TG and ADP- or epinephrine-induced platelet 5-HT release were also increased in MyD patients. These results suggest that an abnormality in release as well as in alpha 2-receptor functioning occurs in the platelets of MyD patients. The relation of this abnormality to changes in Ca2+ fluxes through the platelet membrane is discussed.


Subject(s)
Adenosine Diphosphate/pharmacology , Epinephrine/pharmacology , Myotonic Dystrophy/blood , Platelet Aggregation/drug effects , Adult , Female , Humans , Male , Myotonic Dystrophy/physiopathology , Serotonin/physiology , beta-Thromboglobulin/physiology
13.
Thromb Haemost ; 53(1): 105-9, 1985 Feb 18.
Article in English | MEDLINE | ID: mdl-3158092

ABSTRACT

Plasma beta-thromboglobulin (beta TG) and thromboxane B2 (TXB2) level, platelet aggregation (PA) in platelet rich plasma, platelet survival time using 111Indium radiolabelled platelets and platelet sensitivity to prostacyclin (PGI2) were measured in chronic obstructive arterial disease (COAD) patients. Severity of the disease was assessed by the ankle pressure index using Doppler auscultation. Platelet survival time was shorter, plasma beta TG and TXB2 and the rate and extent of PA induced by ADP or 1-epinephrine (but not collagen) were greater in the patients than in controls. Beta TG was inversly correlated with the pressure index and positively with TXB2 indicating increased platelet TXA2 synthesis. Platelet sensitivity to PGI2 was similar in the patients and controls. These results indicate increased platelet consumption and enhanced in vivo platelet activation and PA in COAD. The enhanced activation correlates with the severity of the disease and the activated platelets presumably synthesize increased amounts of TXA2. It is therefore concluded that platelets might be involved in the pathogenesis of COAD. The normal platelet sensitivity to PGI2 suggests that the administration of the compound may improve the abnormal platelet function in COAD patients and may attenuate the progression of the disease.


Subject(s)
Arterial Occlusive Diseases/blood , Blood Platelets/physiology , Thromboxane B2/blood , Thromboxanes/blood , Adenosine Diphosphate/pharmacology , Aged , Blood Platelets/metabolism , Cell Survival , Epinephrine/pharmacology , Epoprostenol/pharmacology , Female , Humans , In Vitro Techniques , Male , Middle Aged , Platelet Aggregation/drug effects , beta-Thromboglobulin/metabolism
14.
Thromb Haemost ; 52(2): 205-9, 1984 Oct 31.
Article in English | MEDLINE | ID: mdl-6098048

ABSTRACT

The effect of prostaglandin E1 (PGE1) and compound BW245C, adenyl-cyclase activators, theophylline, papaverine and dipyridamole, phosphodiesterase (PDE) inhibitors and pyridoxal-5-phosphate (PALP) on inhibition of platelet aggregation (PA) and platelet c-AMP accumulation was determined in human platelet-rich plasma (PRP) and washed platelets. PGE1 at 280 nM and BW245C at 7.7 nM induced a significant PA inhibition in PRP and washed platelets (though less pronounced by PGE1) concomitant to a very large increase (8-13-fold) in platelet c-AMP level both in PRP and washed platelets. At comparable PA inhibition, c-AMP level was not significantly changed by PALP and only moderately (but significantly) increased (2-4.6-fold) by PDE inhibitors. PALP or theophylline potentiated both PGE1-induced platelet c-AMP accumulation and PA inhibition. Yet PALP potentiated theophylline-induced PA inhibition without affecting platelet c-AMP level. Our results indicate that 2 c-AMP pools are presumably present in the platelets, since at comparable c-AMP accumulation PDE inhibitors or BW245C were more effective than PGE1 in PA inhibition in PRP. Moreover, this pattern was more pronounced in washed platelets and was also found in the presence of thrombin and adenosine diphosphate which induced a decrease in platelet c-AMP level. The effect of PALP on PA inhibition is presumably mediated by 2 mechanisms: a) a direct effect on the platelet membrane independent from the c-AMP system. b) In the presence of PGE1 the increment in PA inhibition, is through further indirect activation of the adenyl-cyclase.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Adenylyl Cyclases/metabolism , Blood Platelets/metabolism , Cyclic AMP/blood , Hydantoins/pharmacology , Phosphodiesterase Inhibitors/pharmacology , Platelet Aggregation/drug effects , Prostaglandins E/pharmacology , Pyridoxal Phosphate/pharmacology , Adult , Alprostadil , Dipyridamole/pharmacology , Female , Humans , Male , Middle Aged , Papaverine/pharmacology , Theophylline/pharmacology
15.
Life Sci ; 35(14): 1497-503, 1984 Oct 01.
Article in English | MEDLINE | ID: mdl-6090838

ABSTRACT

Platelet adenosine-3'-5'-cyclic monophosphate (c-AMP) was determined in platelet rich plasma and washed platelets by a modification of the c-AMP protein binding assay. Studies were performed in the presence and absence of platelet aggregation inducers (adenosine diphosphate and thrombin) and inhibitors (pyridoxal-5-phosphate (PALP), prostaglandin E1 (PGE1), theophylline and papaverine). At 70% inhibitory concentration of platelet aggregation (PA) induced by papaverine or theophylline, a small but significant increase in platelet c-AMP level was found. With PALP however the inhibition of PA was not associated with a significant increase in the c-AMP level. PALP or theophylline potentiated greatly both the inhibition of PA and c-AMP accumulation induced by PGE1. Yet PALP potentiated the inhibition of PA induced by theophylline without increasing platelet c-AMP level. Our results indicate that the inhibition of PA by PALP is not mediated by c-AMP accumulation. However in the presence of PGE1, the increment in PA inhibition, is mediated by further indirect activation of the adenyl-cyclase.


Subject(s)
Blood Platelets/physiology , Cyclic AMP/blood , Platelet Aggregation/drug effects , Pyridoxal Phosphate/pharmacology , Alprostadil , Blood Platelets/drug effects , Humans , Papaverine/pharmacology , Prostaglandins E/pharmacology , Theophylline/pharmacology , Thrombin/physiology
16.
Br J Surg ; 69(1): 38-40, 1982 Jan.
Article in English | MEDLINE | ID: mdl-6274471

ABSTRACT

In a recent double-blind trial lasting over 6 months, 40 patients suffering from intermittent claudication were randomly allocated to receive 300 mg of suloctidil per day or exactly matching placebo capsules. In addition to treadmill walking distance, other objective criteria including ankle blood pressure response and muscle blood flow measured by 133Xe clearance were used to assess the effectiveness of therapy. Nine patients (4 in the suloctidil group and 5 controls) did not complete the trial according to the protocol. Of the remaining 31 patients, 17 were in the control group and 14 received suloctidil. A significant improvement in the absolute walking distance, the level of beta-thromboglobulin (beta TG) compared to pre-therapy value and the time for the ankle pressure index to return to the pre-exercise value was observed in patients receiving suloctidil.


Subject(s)
Intermittent Claudication/drug therapy , Propanolamines/therapeutic use , Suloctidil/therapeutic use , Adult , Aged , Blood Pressure , Clinical Trials as Topic , Double-Blind Method , Female , Humans , Intermittent Claudication/physiopathology , Leg/blood supply , Male , Middle Aged , Physical Exertion , beta-Thromboglobulin/analysis
17.
Br J Surg ; 68(10): 720-4, 1981 Oct.
Article in English | MEDLINE | ID: mdl-7025959

ABSTRACT

The role of prostacyclin and thromboxane during endotoxic shock is unknown. Using new radioimmunoassay techniques, we have studied the plasma levels of stable metabolites of prostacyclin (6-keto-PGF1 alpha) and thromboxane (TxB2) in a porcine model of endotoxic shock. TxB2 levels were markedly elevated but the production of prostacyclin appears to be impaired. Correction of this prostanoid imbalance by the infusion of prostacyclin or pre-treatment with a specific thromboxane synthetase inhibitor produces significant and beneficial effects on blood pressure and pre-kallikrein activation.


Subject(s)
6-Ketoprostaglandin F1 alpha/blood , Shock, Septic/blood , Thromboxane B2/blood , Thromboxanes/blood , Animals , Aorta/metabolism , Blood Pressure/drug effects , Epoprostenol/pharmacology , Kallikreins/blood , Leukocyte Count , Platelet Count , Rabbits , Shock, Septic/physiopathology , Swine , Thromboxane-A Synthase/antagonists & inhibitors
18.
Eur J Clin Invest ; 11(4): 273-7, 1981 Aug.
Article in English | MEDLINE | ID: mdl-6170515

ABSTRACT

Mean levels of beta-thromboglobulin and platelet factor 4 were highly significantly elevated in diabetes compared to controls (72.6 v. 36.3 ng/ml, P less than 0.0005; 48.5 v. 16.5 ng/ml, P less than 0.0005; respectively) as was malondialdehyde formation (12.4 v. 8.1 nmol/10(9) platelets, P less than 0.0005). Diabetes with retinopathy had significantly higher levels of beta-thromboglobulin than those without retinopathy (79 v. 70 ng/ml; P less than 0.042). However, those diabetics without clinical evidence of vascular disease had levels of beta-thromboglobulin and platelet factor 4 significantly higher than controls. beta-Thromboglobulin did not correlate with glycosylated haemoglobin but did correlate significantly with individual lipid and lipoprotein levels (beta-thromboglobulin v. total triglyceride, P less than 0.029; v. VLDL triglyceride, P less than 0.041; v. LDL cholesterol, P less than 0.042; v. HDL/total cholesterol ratio, P less than 0.02). Abnormal platelet function may contribute to the vascular complications of diabetes mellitus.


Subject(s)
Beta-Globulins/analysis , Blood Coagulation Factors/analysis , Diabetes Mellitus/blood , Glycated Hemoglobin/analysis , Lipoproteins/blood , Platelet Factor 4/analysis , beta-Thromboglobulin/analysis , Blood Platelets/metabolism , Cholesterol/blood , Diabetic Retinopathy/blood , Fasting , Female , Humans , In Vitro Techniques , Male , Malondialdehyde/blood , Triglycerides/blood
19.
Haemostasis ; 10(3): 121-33, 1981.
Article in English | MEDLINE | ID: mdl-7262642

ABSTRACT

This study reports the first example of 'storage pool disease' thrombocytopathia B (aspirin-like) in the family of a 4-month-old infant with thrombocytopenic absent radii (TAR) syndrome. In the infant and his father, platelet ADP and 5HT stores were normal, bleeding time was prolonged, released platelet anti-heparin activity, platelet aggregation (PA) to collagen and secondary aggregation to ADP were all significantly decreased and PA to l-epinephrine totally absent. Platelet function studies of the mother, a first cousin to her husband, were normal. This report provides further evidence to the hereditary nature of TAR syndrome. The impaired platelet function is a valuable aid in the diagnosis of TAR syndrome and Fanconi's anaemia.


Subject(s)
Abnormalities, Multiple/blood , Anemia, Aplastic/diagnosis , Blood Platelet Disorders/diagnosis , Fanconi Anemia/diagnosis , Radius/abnormalities , Thrombocytopenia/congenital , Blood Platelets/metabolism , Diagnosis, Differential , Epinephrine/pharmacology , Humans , Infant, Newborn , Male , Platelet Aggregation/drug effects
20.
Am J Med ; 70(1): 59-64, 1981 Jan.
Article in English | MEDLINE | ID: mdl-6450532

ABSTRACT

Plasma level of beta-thromboglobulin (beta TG), a useful marker of in vivo platelet "release reaction,"was determined by radioimmunoassay in 69 patients, with three types of primary hyperlipidemia (IIa, IIb, IV) and compared with the findings in age- and sex-matched healthy controls and 57 patients with established atherosclerosis and peripheral vascular disease. Malondialdehyde (MDA) formation, used for assessment of prostaglandin synthesis, was determined in 51 and plasma platelet factor 4 (PF4), measured by radioimmunoassay, in 48 of the patients with hyperlipidemia. Results were correlated to five serum lipids and lipoprotein levels in the patients with hyperlipidemia. beta TG was significantly increased in the patients with hyperlipidemia and peripheral vascular disease, compared to those in the controls (p < 0.001); it was significantly higher in the patients with hyperlipidemia than in those with peripheral vascular disease. PF4 and MDA formation were also increased in the patients with hyperlipidemia, and significantly higher levels of MDA were obtained in patients with type IIb and type IV hyperlipidemia than in those with type IIa hyperlipidemia (p < 0.02). beta TG and MDA correlated weakly with total serum cholesterol triglycerides and very low density lipoprotein-triglyceride. There was also a significant correlation between beta TG and PF4, and MDA production. These results indicate that in vivo platelet "release reaction" and MDA formation are increased in hyperlipidemic patients. The release reaction is more enhanced in those with hyperlipidemia than in the patients with peripheral vascular disease. They suggest that the abnormal platelet function is related to the elevated levels of serum lipids and lipoproteins in the hyperlipidemic patients and not only to the atherosclerotic changes associated with hyperlipidemia.


Subject(s)
Blood Platelets/metabolism , Hyperlipidemias/blood , Aged , Female , Humans , Male , Malondialdehyde/blood , Middle Aged , Platelet Aggregation , Platelet Factor 4/analysis , Platelet Function Tests , beta-Thromboglobulin/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...